Mitochondrial Apoptosis and Skeletal Muscle Atrophy in Ovarian Cancer: Insights from SkQ1 Intervention

Study Background and Research Question

Skeletal muscle atrophy is a significant complication in advanced cancer, contributing to patient morbidity and decreased quality of life. Although regulated cell death pathways—including apoptosis and necroptosis—have been implicated in muscle wasting, the specific contribution of mitochondrial-linked signaling remains unresolved. The reference study by Khajehzadehshoushtar et al. (J Physiol, 2025) addresses whether mitochondrial-derived hydrogen peroxide (mH₂O₂)-mediated apoptotic and necroptotic signaling are causally involved in skeletal muscle atrophy during the progression of epithelial ovarian cancer (EOC) in a mouse model.

Key Innovation from the Reference Study

This research provides one of the first systematic evaluations of time-dependent, muscle-specific mitochondrial apoptotic and necroptotic pathways in cancer-induced atrophy, utilizing a mitochondrial-targeted antioxidant (SkQ1) as a mechanistic probe. The study distinguishes between early and late-stage EOC, directly measuring mitochondrial H₂O₂ emission, caspase activities, and muscle fiber atrophy, thereby clarifying the temporal and causal relationships between these cellular events.

Methods and Experimental Design Insights

The investigators employed a robust orthotopic mouse model of metastatic ovarian cancer, focusing on the white gastrocnemius muscle, rich in type IIB fibers. Mice were divided into early- and late-stage EOC groups, with or without chronic administration of SkQ1 via drinking water. Key methods included:

• Quantification of mitochondrial H₂O₂ emission (mH₂O₂) from isolated muscle mitochondria.
• Assessment of mitochondrial permeability transition (mPT) probability, a marker of mitochondrial vulnerability to stress.
• Measurement of caspase-9 and -3 activities to index the extent of mitochondrial apoptotic signaling.
• Evaluation of necroptosis markers (RIPK1 and phosphorylated RIPK3) through immunoblotting.
• Histological determination of muscle fiber cross-sectional area (CSA) to quantify atrophy.

This multifaceted approach allowed for precise temporal mapping of molecular and physiological events in cancer-induced muscle loss.

Core Findings and Why They Matter

The study's central findings can be summarized as follows:

• Early-stage EOC: Type IIB fiber CSA was reduced (indicative of atrophy), but mitochondrial H₂O₂ emission was unaltered, despite increased caspase-9 and -3 activities.
• Late-stage EOC: Sustained fiber atrophy was accompanied by elevated mitochondrial H₂O₂ emission, increased mPT probability, and persistently high caspase-9 and -3 activities.
• SkQ1 treatment: This mitochondrial-targeted antioxidant normalized mitochondrial H₂O₂ levels and reduced caspase-9 and -3 activities at late-stage, but had no effect on muscle fiber atrophy.
• Necroptosis markers: RIPK1 was transiently increased in early-stage EOC, while phosphorylated RIPK3 decreased in late-stage, with no consistent pattern or modification by SkQ1.

These findings suggest that while mitochondrial apoptotic signaling (via caspase-9 and -3) and oxidative stress markers are elevated during EOC progression, their normalization does not prevent muscle atrophy. This challenges the hypothesis that mitochondrial apoptosis is the principal driver of cancer-induced muscle loss, at least in type IIB-rich fibers. The heterogeneity and lack of consistent change in necroptosis markers further indicate that necroptosis is not a primary pathway in this context.

Importantly, the onset of atrophy prior to detectable increases in mH₂O₂ emission underscores the need to re-evaluate the temporal assumptions about oxidative stress and cell death in muscle wasting during cancer.

Comparison with Existing Internal Articles

Existing resources, such as Z-IETD-FMK: Precision Caspase-8 Inhibition in Apoptosis Research and Z-IETD-FMK: Precision Caspase-8 Inhibition for Immune Research, highlight the utility of Benzyloxycarbonyl-Ile-Glu(OMe)-Thr-Asp(OMe)-fluoromethylketone (Z-IETD-FMK) for dissecting caspase-8–dependent apoptotic and immune signaling pathways. These articles underscore the specificity of Z-IETD-FMK in inhibiting caspase-8, enabling detailed study of T cell proliferation inhibition, NF-κB signaling modulation, and apoptosis in various immune and cancer models.

However, the reference study extends the mechanistic focus beyond caspase-8, emphasizing the roles of downstream caspases-9 and -3 in the context of mitochondrial apoptosis in muscle atrophy. While Z-IETD-FMK is not directly employed in the reference work, its use in parallel experimental systems could facilitate complementary studies—particularly in distinguishing the specific contributions of initiator versus effector caspases and in immune cell activation research. Internal articles further provide practical assay optimization strategies and troubleshooting for apoptosis research, which remain relevant for designing mechanistic investigations inspired by the reference study's findings.

Limitations and Transferability

Several important limitations must be considered. The study focused exclusively on type IIB-rich gastrocnemius muscle in a mouse model of EOC, restricting the generalizability of findings to other muscle types or cancer models. The temporal dissociation between atrophy and oxidative/apoptotic markers suggests the involvement of alternative or parallel pathways not captured by the current assays. Additionally, while SkQ1 effectively modulated mitochondrial redox and apoptotic signaling, off-target effects or compensatory mechanisms could influence the observed outcomes.

Transferability to clinical or other experimental settings requires careful consideration of muscle fiber heterogeneity, cancer type, disease stage, and the selection of molecular endpoints. The results do not preclude non-apoptotic or non-necroptotic roles for caspases in muscle atrophy, nor do they exclude the involvement of these pathways in other muscle groups or disease contexts.

Protocol Parameters

• SkQ1 administration: Delivered via drinking water throughout early and late EOC stages; dosing regimens should be based on prior pharmacokinetic and toxicity data for mitochondrial-targeted antioxidants.
• Muscle sample collection: Harvest type IIB-rich gastrocnemius muscle for mitochondrial isolation and histological analysis.
• Caspase activity assays: Quantify caspase-9 and -3 enzymatic activities as primary readouts for mitochondrial apoptotic signaling.
• Oxidative stress assessment: Measure mitochondrial H₂O₂ emission using established fluorometric or chemiluminescent protocols.
• Necroptosis evaluation: Analyze RIPK1 and phosphorylated RIPK3 by immunoblot; interpret data with caution given observed heterogeneity.
• Atrophy quantification: Use fiber cross-sectional area measurement on histological sections to detect muscle wasting.

Outlook: Implications and Remaining Questions

The findings from Khajehzadehshoushtar et al. (2025) call for a nuanced understanding of apoptosis in cancer cachexia. While mitochondrial-targeted antioxidants can suppress apoptotic signaling, their inability to rescue muscle mass suggests that therapies focused solely on mitochondrial apoptosis may not suffice to prevent atrophy. Further research should explore non-apoptotic functions of caspases, alternative cell death pathways, and fiber-type–specific vulnerabilities. The study also highlights the importance of temporal resolution in the analysis of disease progression and interventional efficacy.

Research Support Resources

For researchers aiming to dissect the molecular mechanisms underlying apoptosis or immune cell activation in similar models, Z-IETD-FMK (SKU B3232) offers a potent, specific tool for caspase-8 inhibition. Available from APExBIO, this inhibitor is well-suited for studies requiring precise modulation of T cell proliferation and NF-κB signaling, as highlighted in several internal resources. Its robust solubility and performance in both in vitro and in vivo settings make it a valuable addition to apoptosis and immune cell signaling workflows. Researchers should tailor inhibitor selection and dosing protocols to their specific experimental context for optimal reproducibility and mechanistic clarity.